e-learning
resources
Vienna 2012
Monday, 03.09.2012
Management of severe respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy
O. Kilinc, O. Soylar, A. Cilli, A. Sakar, S. Tasbakan, H. Ellidokuz, B. Celenk, C. Cetinkaya, C. Gunduz, A. Sayiner (Izmir, Antalya, Manisa, Turkey)
Source:
Annual Congress 2012 - Management of severe respiratory infections
Session:
Management of severe respiratory infections
Session type:
Thematic Poster Session
Number:
2453
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Kilinc, O. Soylar, A. Cilli, A. Sakar, S. Tasbakan, H. Ellidokuz, B. Celenk, C. Cetinkaya, C. Gunduz, A. Sayiner (Izmir, Antalya, Manisa, Turkey). Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy. Eur Respir J 2012; 40: Suppl. 56, 2453
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP)
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 135-143
Year: 2003
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Difference of patient background with pneumonia between monotherapy and combination
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Efficacy of α-tocoferol in the treatment of patients with pneumonia
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
Source: Eur Respir J 2004; 24: Suppl. 48, 185s
Year: 2004
The usage of laferon in treatment of patients with community acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 675s
Year: 2007
Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo
Source: Eur Respir J 2003; 22: Suppl. 45, 335s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept